Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘CDK2’

AACR25 – Preview 1

Chicago!

AACR 2025 is in Chicago – it’s time for our first impressions from the Windy City abstracts.

The American Association for Cancer Research (AACR) Annual Meeting will be bringing together thousands of researchers, clinicians, and industry leaders at the forefront of cancer innovation.

As the conference timeline unfolds, we’re sifting through the huge wealth of data in the abstracts being presented to bring you our specialised analyses of the most impactful developments and watch to watch out for.

In this first preview, we explore an emerging area gaining significant momentum of late.

With over 50 abstracts in this space alone, the diversity of approaches signals both the enthusiasm and the evolving strategies companies are employing to translate these elegant mechanisms into clinical reality.

From established targets to previously tricky to target proteins, the presentations this year reveal much about where this field is heading – and which approaches might ultimately deliver for patients…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The scudding clouds of freedom

All too often the noise and attention is thrust upon the latest flashy or shiny new lures rather than on refining or redirecting the sails based upon changes in the wind patterns as more data become available.

In the book Dracula, Bram Stoker wrote:

“…the passing gleams of the moonlight between the scudding clouds crossing and passing, [are] like the gladness and sorrow of a man’s life.”

He might just as well been referring to drug company pipelines, where early stage agents rise and fall in favour as we follow their trials and tribulations from discovery and preclinical development through to evaluation in the clinic.  Success is fleeting and more often than not, many will fizzle and disappear in the blink of an eye.

Sometimes though, new information or intelligence comes together to point a different way forward.  It’s not necessarily going to be ‘better’, but like other aspects of life, taking action and moving forward is usually a sounder strategy than standing still.

Here, we look at a couple of developments that seemingly hit the skids a few years ago, but new evidence may offer some more focused direction forward…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The road less travelled

The path less travelled can take us in interesting and unknown directions

We often talk about innovation on BSB and how hard it is to blaze a new path in oncology drug development.

Sometimes what it requires is a different way to think about a target or a new approach to modulating a pathway.

In our latest post AACR23 review, we are taking a closer look at more gems from the poster hall and how some companies and researchers are thinking differently.

Taking the road less travelled is inevitably a balance of risk and reward with plenty of challenges to overcome, which by definition is part of what makes oncology new product development such a challenging yet stimulating area…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

Springing between meetings

This time of year always brings a flurry of data across different conferences as we start winding up our AACR coverage, spring forward to the ASCO abstract title drop and prepare for the forthcoming ASGCT meeting.

Of course, much like the weather of late there are always uncertainties involved when looking at abstract titles.

We may know, for example, that certain trials have been announced as positive having met their pre-defined criteria, but as to the exact magnitude of the effect and how much benefit is actually offered in terms of outcomes is another story entirely!

It would be impossible to review all of the meeting in one go, hence we’ll be offering a series of snapshots and discussion highlighting different key topics over the next few weeks.

Here are our notes on the first one in the series…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Sticking it to MYC addicted cancers and other targets

Two people can look at a mountain and see it differently

We have written quite a bit about protein degradation and molecular glues over the last two years, including sharing our findings, analysis and discussions with various company and academic expert interviews.

This time around it’s time to look at another biotech active in this space, albeit with completely different targets and approaches than what we have covered in detail previously.

We also look at what makes a great target from their perspective and how a deep understanding of certain elements may give them an advantage.

One of the beauties of this niche for me is not everyone is doing the exact same thing and there’s plenty of room for novel ideas to flourish and be investigated in both discovery and clinical phases.

So what’s unique about this company and why should you pay attention to what they are doing?

BSB subscribers can read more on our latest discussion around some novel early stage pipeline targets plus a company interview – you can log-in or click to access our latest content.

This content is restricted to subscribers

Highlights and commentary on key AACR21 data presentations

It’s time for some commentary and insights regarding important emerging data from the AACR meeting.

The route to success in oncology R&D is always paved with gold, after all, although big ticket acquisitions may take some of the sting out of the tail.

As always, there were some hidden gems in the AACR21 program — in the first of our post meeting critiques, we take a careful look at the what’s behind the veneer.

We have a round baker’s dozen of early new product development compounds and explore them all to find out what interesting, as well as where there are potential pointers for future challenges which may need to be addressed…

To learn more about the AACR21 data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Building up a storm against resistant solid tumours

Can we build up a storm against hard to treat cancers?  The initial evidence suggests, yes we can!

Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to treat solid tumours with a more selective and focused approach to oncology drug development.

We’ve talked about the so-called ‘drugging the undruggable’ targets in the past, but what if we could circle back and use a different approach in combination with existing selective inhibitors currently in the clinic?

These possibilities – and others – caught my attention and they may pique yours too, so what’s this all about?

To learn more from our oncology analysis and get a heads up on insights and commentary emerging on protein degradation, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!